IMMUNOVANT INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Immunovant, Inc. - IMVT
Immunovant, Inc. (IMVT)
Company Research
Source: GlobeNewswire
NEW YORK and NEW ORLEANS, Sept. 17, 2025 (GLOBE NEWSWIRE) -- The law firm of Kahn Swick & Foti, LLC (“KSF”) has commenced an investigation into Immunovant, Inc. (NasdaqGS: IMVT) (“Immunovant”). KSF is investigating whether Immunovant’s officers and/or directors breached their fiduciary duties or otherwise violated state or federal laws. If you hold shares of Immunovant, Inc. (NasdaqGS: IMVT), we urge you to contact KSF to discuss your legal rights, without obligation or cost to you, by calling KSF toll-free at 1-833-938-0905, or by e-mailing KSF Managing Partner, Lewis Kahn, (lewis.kahn@ksfcounsel.com), or visit https://www.ksfcounsel.com/cases/nasdaqgs-imvt/ to learn more. About Kahn Swick & Foti, LLC KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation's premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a vari
Show less
Read more
Impact Snapshot
Event Time:
IMVT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMVT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMVT alerts
High impacting Immunovant, Inc. news events
Weekly update
A roundup of the hottest topics
IMVT
News
- Oppenheimer Maintains Outperform Rating on Immunovant (IMVT) Following Q2 2026 Earnings [Yahoo! Finance]Yahoo! Finance
- Immunovant Provides Corporate Updates and Reports Financial Results for the Second Quarter Ended September 30, 2025 [Yahoo! Finance]Yahoo! Finance
- Roivant Reports Financial Results for the Second Quarter Ended September 30, 2025, and Provides Business Update [Yahoo! Finance]Yahoo! Finance
- Immunovant Provides Corporate Updates and Reports Financial Results for the Second Quarter Ended September 30, 2025GlobeNewswire
- Immunovant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025GlobeNewswire
IMVT
Earnings
- 11/10/25 - Miss
IMVT
Analyst Actions
- 9/30/25 - JP Morgan
IMVT
Sec Filings
- 12/3/25 - Form 4
- 12/3/25 - Form 4
- 12/1/25 - Form 144
- IMVT's page on the SEC website